It’s estimated that 90% of retail investors lose money. We help you beat those odds with concise research, education and more. Click here to see our offerings.
- A diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need
- Lead asset = SYN-004 (ribaxamase) is an oral therapy in P2 of development
- Designed to degrade IV antibiotics while maintaining the natural balance of the gut microbiome and providing other benefits
- Second asset = SYN-020 an oral therapy in P1a of development